Stifel Reiterates Alnylam Pharmaceuticals (ALNY) at Buy, "We Believe Biologically Onpattro Should be Best-in-Class"
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $215.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY)The analyst quotes: "The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
